Table of Contents
Definition / general | Essential features | Terminology | ICD coding | Epidemiology | Sites | Etiology | Clinical features | Diagnosis | Radiology description | Radiology images | Prognostic factors | Case reports | Treatment | Gross description | Frozen section description | Intraoperative frozen / smear cytology images | Microscopic (histologic) description | Microscopic (histologic) images | Cytology description | Positive stains | Negative stains | Electron microscopy description | Molecular / cytogenetics description | Molecular / cytogenetics images | Sample pathology report | Differential diagnosis | Additional references | Board review style question #1 | Board review style answer #1 | Board review style question #2 | Board review style answer #2Cite this page: Multz RA, Ahrendsen JT. Pineoblastoma. PathologyOutlines.com website. https://www.pathologyoutlines.com/topic/cnstumorpineoblastoma.html. Accessed November 27th, 2024.
Definition / general
- Malignant embryonal neoplasm of the pineal gland (CNS WHO grade 4)
Essential features
- Malignant embryonal neoplasm (CNS WHO grade 4)
- High mitotic index
- Located in pineal region
Terminology
- Pineoblastoma
ICD coding
- ICD-O: 9362/3 - pineoblastoma
- ICD-10: C75.3 - malignant neoplasm of pineal gland
- ICD-11: 2A00.20 & XH1ZH1 - tumors of the pineal gland or pineal region & pineoblastoma
Epidemiology
- Pineal tumors are rare, representing < 1% of all CNS neoplasms (Neuro Oncol 2023;25:iv1)
- Pineoblastoma represents ~30 - 35% of all pineal parenchymal tumors
- Pineoblastoma typically arise in children / adolescents, with the overall median age of 6 years, depending on the molecular subtype (Acta Neuropathol 2021;141:771)
- miRNA processing altered 1: 8.5 years old
- miRNA processing altered 2: 11.6 years old
- RB1 altered: 2.1 years old
- MYC / FOXR2 activated: 1.3 years old
Sites
- Pineal gland
- Cerebrospinal fluid (CSF) dissemination in 25 - 30% of patients with possible leptomeningeal disease as well as distant spinal metastases (BMJ Case Rep 2015;2015:bcr2015210343, Arch Pathol Lab Med 2001;125:939)
Etiology
- Can be associated with DICER1 tumor predisposition syndrome (Acta Neuropathol 2021;141:771)
- RB1 altered subgroup can be seen in association with germline RB1 mutations (Acta Neuropathol 2020;139:243)
- Rare cases in patients with familial adenomatous polyposis (Dis Colon Rectum 2005;48:2343)
Clinical features
- Patients typically present with features of increased intracranial pressure and obstructive hydrocephalus (headache, nausea, vomiting, papilledema) (Childs Nerv Syst 1998;14:53, Coll Antropol 2013;37:35)
- If the tumor compresses the superior colliculus, patients may present with Parinaud syndrome (upward gaze palsy) (Adv Exp Med Biol 2023;1405:153)
Diagnosis
- Brain imaging, usually magnetic resonance imaging (MRI)
- Biopsy / resection specimen
Radiology description
- Large, irregular, lobulated mass with varying degrees of calcification and ill defined borders with adjacent structures (Neuroradiology 2000;42:509)
- Weak / heterogeneous contrast enhancement on MRI and CT (Neuroradiology 2000;42:509)
- T1: isointense to hypointense relative to adjacent brain
- T2: hypointense relative to adjacent brain
- Frequently associated with obstructive hydrocephalus (J Comput Assist Tomogr 1995;19:509)
Radiology images
Prognostic factors
- Young patient age, disseminated disease at diagnosis and subtotal surgical resection are important negative prognostic factors (Cancer 2012;118:173, Clin Transl Oncol 2012;14:827)
- Median overall survival (OS): 4.1 - 8.7 years; 5 year overall survival: 10 - 81% (World Neurosurg 2014;82:1232, Pediatr Blood Cancer 2015;62:776)
- Staging (based on the Chang system for medulloblastoma) (Radiology 1969;93:1351)
- M0: no evidence of gross subarachnoid or hematogenous metastases
- M1: microscopic tumor cells in CSF
- M2: gross nodular disease seen in cerebral / cerebellar subarachnoid space or in third / lateral ventricles
- M3: gross nodular disease seen in spinal subarachnoid space
- M4: metastases outside of the CNS
- Clinical outcomes vary by molecular subgroup (Acta Neuropathol 2021;141:771)
- miRNA processing altered 1: intermediate prognosis (median OS: 10.4 years, 5 year OS: 68%)
- miRNA processing altered 2: favorable prognosis (median OS: not reached, 5 year OS: 100%)
- RB1 altered: poor prognosis (median OS: 2.8 years, 5 year OS: 29%)
- MYC / FOXR2 activated: poor prognosis (median OS: 1.2 years, 5 year OS: 23%)
Case reports
- 2 year old boy who received a multivisceral transplant (Pediatr Transplant 2012;16:E110)
- 3 year old girl with pineal anlage tumor (Childs Nerv Syst 2022;38:1625)
- 15 year old girl with pineoblastoma diagnosed by CSF cytology (Cytopathology 2024;35:421)
- Pineoblastoma without retinoblastoma in a patient with germline RB1 mosaicism (JAMA Ophthalmol 2022;140:437)
Treatment
- Surgery, adjuvant craniospinal irradiation (CSI) and chemotherapy (Acta Neuropathol 2020;139:259)
Gross description
- Soft, friable, tan-pink to tan-gray mass
- May show areas of hemorrhage or necrosis (Cancer 1980;45:1408)
Frozen section description
- Densely cellular, poorly differentiated neoplasm with numerous mitoses, necrosis, hyperchromasia and high N:C ratio
Intraoperative frozen / smear cytology images
Microscopic (histologic) description
- Hypercellular, poorly differentiated, small, round blue cell tumor (embryonal morphology)
- High N:C ratio, nuclear molding, brisk mitotic activity, necrosis
- Homer-Wright rosettes (eosinophilic material as false lumen) and less commonly Flexner-Wintersteiner rosettes (true lumen formation)
- May or may not see invasion of adjacent brain
- Reference: Brain Pathol 2000;10:49
Microscopic (histologic) images
Cytology description
- Primitive appearing cells will show high N:C ratio, brisk mitotic activity and necrosis (Cytopathology 2023 Dec 15 [Epub ahead of print])
- Large, round to oval cells with granular cytoplasm, course chromatin, inconspicuous nucleoli and nuclear molding (Cytopathology 2024;35:421)
- Sheet-like architecture and the presence of Homer-Wright rosettes may or may not be appreciated by cytology
Positive stains
- Synaptophysin
- Neuron specific enolase (NSE)
- Neurofilament (variable)
- Chromogranin A (variable) (Neuropathology 2002;22:66)
- CRX (Am J Surg Pathol 2017;41:1410)
- INI1 (SMARCB1)
- BRG1 (SMARCA4) (Brain Pathol 2013;23:19)
- Ki67 (high labeling index) (Clin Neuropathol 2008;27:325)
Negative stains
- GFAP
- Olig2
- Cytokeratins
- LIN28A (Neuropathology 2002;22:66)
Electron microscopy description
- No longer used in routine clinical practice
Molecular / cytogenetics description
- 4 distinct subgroups of pineoblastoma with peculiar genetic alterations have been identified using DNA methylation profiling (Acta Neuropathol 2020;139:223, Acta Neuropathol 2020;139:243, Acta Neuropathol 2021;141:771)
- miRNA processing altered 1, characterized by
- Pathogenic germline variant in DICER1 or mutually exclusive mutations in DICER1, DROSHA and DGCR8
- Gains of chromosomes 7 and 12, loss of chromosomes 16 and 22q
- miRNA processing altered 2
- Pathogenic germline variant in DICER1 or alterations in DICER1 and DROSHA (loss of function)
- Loss of chromosomes 8, 14q, 16 and 20
- RB1 altered
- Germline pathogenic variant in RB1 variant or somatic RB1 alteration or gain of miR17 / 92
- Gains of chromosomes 1q and 6p and loss of chromosome 16
- MYC / FOXR2 activated
- FOXR2 overexpression or MYC amplification
- Gains of 8q and loss of 16q
- miRNA processing altered 1, characterized by
Sample pathology report
- Brain, pineal tumor, resection / biopsy:
- Pineoblastoma, CNS WHO grade 4, molecular subgroup miRNA processing altered 1
Differential diagnosis
- Pineal parenchymal tumor of indeterminate differentiation:
- Can be hypercellular but has less cytologic atypia and lower mitotic activity, minimal to no rosette formation and no necrosis
- KBTBD4 mutation, which is absent in pineoblastoma (Acta Neuropathol 2020;139:243)
- Medulloblastoma:
- Localized in the posterior fossa by definition
- May harbor alterations in SHH and WNT pathways
- Unique DNA methylation profiles
- Lacks CRX immunohistochemical expression
- Atypical teratoid / rhabdoid tumor:
- Loss of INI1 (SMARCB1) expression or BRG1 (SMARCA4) expression
- Variably positive for GFAP and cytokeratins
- Embryonal tumor with multilayered rosettes:
- LIN28A positive
- C19MC alteration
- Diffuse midline glioma, H3 K27 altered:
- Demonstrates glial marker expression (GFAP, Olig2)
- Harbors H3 K27M mutation (immunohistochemistry or molecular)
- Lacks CRX expression (Pediatr Dev Pathol 2014;17:85)
Additional references
Board review style question #1
A 5 year old boy presents with an intracranial mass that appears to arise adjacent to the splenium of the corpus callosum. A resection is performed and shows the tumor morphology above. The tumor cells are positive for synaptophysin, NSE and INI1 and negative for GFAP and Olig2. What is the most likely molecular alteration in this tumor?
- Biallelic loss of SMARCB1
- DICER1 mutation
- H3 K27M mutation
- IDH1 R132H mutation
- SHH pathway activation
Board review style answer #1
B. DICER1 mutation. The microscopic image shows a tumor of the pineal region with high N:C ratio, nuclear molding and numerous apoptotic bodies. The morphologic and anatomic features of the tumor, combined with the patient’s young age, indicate that this tumor is most likely a pineoblastoma. DICER1 mutations can be seen in both the miRNA processing altered 1 and miRNA processing altered 2 subgroups of pineoblastoma.
Answer D is incorrect because IDH1 R132H mutations are typically seen in adult type diffuse gliomas, which are uncommon in children and are positive for GFAP and OLIG2.
Answer A is incorrect because biallelic loss of SMARCB1 is seen in atypical teratoid / rhabdoid tumors, which can be seen in young children and can show some morphologic overlap with pineoblastoma; however, these tumors show loss of INI1 by immunohistochemistry and are variably positive for GFAP.
Answer E is incorrect because SHH pathway activation is seen in a subset of medulloblastoma. They typically arise in the posterior fossa of younger children but can show significant morphologic overlap with pineoblastoma.
Answer C is incorrect because H3 K27M alterations are seen in diffuse midline gliomas, which are positive for Olig2 and can show variable positivity for GFAP.
Comment Here
Reference: Pineoblastoma
Comment Here
Reference: Pineoblastoma
Board review style question #2
A 5 year old boy presents with symptoms of increased intracranial pressure. Brain imaging reveals a mass centered in the pineal region and biopsy reveals a diagnosis of pineoblastoma. Which of the following immunostains is most specific for this diagnosis?
- Beta catenin
- CRX
- H3 K27M
- INI1
- LIN28A
Board review style answer #2
B. CRX. CRX is a transcription factor involved in retinal and pineal lineage differentiation. It is often diffusely positive in pineoblastoma and other pineal parenchymal tumors. Answer A is incorrect because aberrant nuclear beta catenin expression is generally observed in adamantinomatous craniopharyngioma and WNT activated medulloblastoma. Answer D is incorrect because loss of nuclear INI1 expression is commonly seen in atypical teratoid / rhabdoid tumors. Answer E is incorrect because LIN28A expression is commonly observed in embryonal tumors with multilayered rosettes and a subset of other tumors but is negative in pineoblastoma. Answer C is incorrect because H3 K27M is generally encountered in diffuse midline glioma, not pineoblastoma.
Comment Here
Reference: Pineoblastoma
Comment Here
Reference: Pineoblastoma